Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

The Finviz API:   Higher Limits, Clearer Data, and More Ways to Connect

Get Started Now
Market News Market Pulse Stocks News ETF News Crypto News

Kalaris Therapeutics, Inc.

Contributing Author

Recent Articles by Kalaris Therapeutics, Inc.

Aug-31
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference KLRS GlobeNewswire
Aug-11
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates KLRS GlobeNewswire
Jul-20
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer KLRS -8.68% GlobeNewswire
Jul-17
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts KLRS GlobeNewswire
Jul-06
Kalaris Appoints Laurie Keating to Board of Directors KLRS GlobeNewswire
Jun-23
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling KLRS GlobeNewswire
Jun-12
Kalaris to Present at Clinical Trials at the Summit 2026 KLRS GlobeNewswire
May-12
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates KLRS GlobeNewswire
Jan-28
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting KLRS GlobeNewswire
Dec-17
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement KLRS +20.32% GlobeNewswire
Dec-17
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naive Neovascular AMD KLRS +20.32% GlobeNewswire
Nov-12
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates KLRS GlobeNewswire
Nov-03
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer KLRS GlobeNewswire
Oct-30
Kalaris to Present at Stifel 2025 Annual Healthcare Conference KLRS GlobeNewswire
Sep-15
UPDATE - Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration KLRS KLRS +35.04% GlobeNewswire
Sep-15
Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration KLRS GlobeNewswire
Aug-13
Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates KLRS -8.43% GlobeNewswire
Jun-02
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference KLRS GlobeNewswire
May-23
Kalaris to Participate at Stifel Ophthalmology Forum KLRS GlobeNewswire
May-14
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights KLRS GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)